Inactivated virosome hepatitis A vaccine.
Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and tolerability of an IRIV-HAV vaccine and the effectiveness of a booster by immunising 104 healthy HAV seronegative volunteers. A single dose was highly immunogenic, since 98% of volunteers had seroconverted after 2 weeks. Anti-HAV titres remained high, with 100% seroconversion rate 1 year later, when the booster was given. The vaccine was effective, with a 22-fold increase in geometric mean titres 1 month later. No serious adverse reactions were observed.
Loutan
L
L
Department of Medicine, Hôpital Cantonal Universitaire de Genève, Switzerland.
Bovier
P
P
Althaus
B
B
Glück
R
R
D000276:Adjuvants, Immunologic; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis; D004337:Drug Carriers; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006506:Hepatitis A / Q000517:prevention & control*; D017957:Hepatitis A Virus, Human / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D009980:Influenza A virus / Q000276:immunology; D008297:Male; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D014771:Virion / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004337:Drug Carriers; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines